Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
64.5 EUR | -2.27% | -21.89% | -32.31% |
06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
06-18 | Kepler Cheuvreux Upgrades Carl Zeiss Meditec to Buy from Reduce, Cuts PT | MT |
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2024 P/E ratio at 27.65 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.31% | 6.38B | - | ||
+7.23% | 217B | B | ||
+11.31% | 191B | B- | ||
+28.94% | 154B | B- | ||
+32.00% | 112B | A- | ||
-0.76% | 62.84B | A- | ||
+16.09% | 53.34B | B+ | ||
+0.80% | 48.83B | B+ | ||
+1.23% | 35.73B | - | ||
+23.40% | 31.18B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- AFXA Stock
- Ratings Carl Zeiss Meditec AG